Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 4Carcinoma, Hepatocellular 2Tuberous Sclerosis 1Recurrence 1Prostate Cancer Patients 1Neoplasms 1Lymphangioleiomyomatosis 1Glioma 1Glioblastoma 1Cholangiocarcinoma 1Brain Neoplasms 1

Interventions

Everolimus 18Sirolimus 15Cannabidiol 5radiprodil 3ganaxolone 3Vigabatrin 3Activator Appliances 3Melatonin 2exemestane 1dactolisib 1carbon-11 acetate 1Surveys and Questionnaires 1Simvastatin 1Sertraline 1Selective Serotonin Reuptake Inhibitors 1Propranolol 1Itraconazole 1Injections 1Fluid Therapy 1Doxycycline 1Curcumin 1Carbamazepine 1Calcitriol 1Aspirin 1Anticonvulsants 1Actigraphy 1Acceptance and Commitment Therapy 12-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Tuberous Sclerosis × carbon-11 acetate × Clear all
NCT05467397 2026-01-21

Feasibility of [11C]Acetate-PET in LAM and TSC

Brigham and Women's Hospital

Phase 1/2 Active not recruiting
7 enrolled 6 charts

Tuberous Sclerosis, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡